Receive our newsletter – data, insights and analysis delivered to you
June 1, 2009

Lilly’s Gemzar shows Positive Results for Cervical Cancer

Eli Lilly has announced that the addition of Gemzar to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer. The phase III trial data conducted on 515 patients showed a signif

By cms admin

Eli Lilly has announced that the addition of Gemzar to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.

The phase III trial data conducted on 515 patients showed a significant increase in progression-free survival at three years for patients treated with the gemcitabine chemoradiation combination versus those treated only with chemoradiation.

Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities.

Eli Lilly vice-president of cancer research and global oncology platform leader Richard Gaynor said that “Lilly continues to look for ways to improve the survival of people living with cancer and fill unmet needs in difficult-to-treat cancers”.

Results from this global, multicentre, open-label, randomised Phase III trial were presented at the 45th Annual Meeting of the American Society of Clinical Oncology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU